BioMérieux BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Becomes First COVID-19 Diagnostic Test to Obtain De Novo FDA Authorization
|
By HospiMedica International staff writers Posted on 19 Mar 2021 |

Image: BIOFIRE RP2.1 Panel (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has received US Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel, making it the first SARS-CoV-2 diagnostic test of any kind to be granted De Novo status by US FDA.
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Framework Aims to Turn Medical Care from Reactive to Preventive
Health systems face rising burdens from aging populations, chronic disease, and workforce shortages. Medical artificial intelligence (AI) remains concentrated in diagnosis and decision support, leaving... Read more
AI Model Predicts Indwelling Catheter Use After Spinal Cord Injury
Patients with early-stage spinal cord injury and neurogenic bladder often face uncertain trajectories in urinary catheter management. Clinicians need tools to anticipate conversion to indwelling catheters... Read moreCritical Care
view channel
Patch-Based Therapy Promotes Myelin Repair in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease that damages the myelin sheath in the central nervous system, leading to progressive disability. After inflammatory attacks, remyelination is often... Read more
Remote Cardiac Device Monitoring System Shows Safety and Cost Benefits
Regular in-clinic follow-up for patients with cardiac implantable electronic devices, including pacemakers and implantable cardioverter defibrillators, is resource intensive. As device use rises with aging... Read moreSurgical Techniques
view channel
Nanobone Material Activates Natural Repair Signals to Regrow Bone
Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more
First Robotic Dual Liver-Kidney Transplant Expands Minimally Invasive Transplant Surgery
Patients with end-stage liver disease often develop renal failure, creating the need for simultaneous liver-kidney transplantation. Traditional open dual-organ transplantation requires large incisions... Read morePatient Care
view channel
Weighted Blankets Reduce Anxiety in Hospitalized Adults
Anxiety is common among hospitalized adults and can impair recovery, disrupt sleep, and worsen mental health. Although clinicians often use nonpharmacologic strategies, bedside options that act quickly... Read more
Multicenter Study Quantifies Delays in Care for Emergency Department Boarders
Emergency department (ED) boarding—the practice of keeping admitted patients in the ED while awaiting an inpatient bed—creates hazardous delays in definitive care. Prolonged transitions expose older and... Read moreMedical Imaging
view channel
Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis
Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
AI-Guided Ultrasound Enables Nonexpert Screening for Aortic Stenosis
Aortic stenosis is a narrowing of the aortic valve that can progress silently until advanced disease. Comprehensive echocardiography is the diagnostic standard, but it requires specialized equipment and... Read moreHealth IT
view channel
Nurse-Coordinated Care Model Improves Heart Failure Outcomes
Heart failure imposes heavy mortality, morbidity, and cost burdens worldwide, yet proven therapies remain underused in routine practice. This inadequate uptake contributes to preventable hospitalizations... Read more
Imaging Tool Quantifies Calcinosis Cutis Volume to Monitor Treatment
Calcinosis cutis involves calcium deposits in the skin or soft tissues that can develop anywhere in the body, causing pain, impaired mobility, and disability. Lesions along the spine or buttocks can make... Read morePoint of Care
view channel
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read more
Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices
Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. These limitations can slow diagnosis and restrict use... Read moreBusiness
view channel
Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award
Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more








